Figure 1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Year: 2025
Type: other
Abstract: OS and duration of response. Patients were treated according to the (A) study schema. B, OS and (C) duration of response among patients who achieved CR + CRh + CRi. The median OS for all patients (n = 27) was 7.6 months (95% CI, 3.3–13.4) with a median follow-up of 9 months. Additional parameters are listed in Table 3.
Authors: Eric D. Eisenmann, Ronan Swords, Ying Huang, Shelley Orwick, Daelynn Buelow, Nicole Abbott, Mitch Phelps, Joshua Zeidner, Matthew C. Foster, Tara L. Lin, Maria R. Baer, Yazan F. Madanat, Tibor Kovacsovics, Robert Redner, Zeina Al-Mansour, Bhavana Bhatnagar, Mona Stefanos, Molly Martycz, Franchesca Druggan, Timothy L. Chen, Ashley O. Yocum, Uma Borate, Brian J. Druker, Amy Burd, Ross L. Levine, John C. Byrd, Sharyn D. Baker, Alice S. Mims
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4412385398